Polaryx Therapeutics Inc（以下简称Polaryx）宣布，其针对Soteria篮子试验计划评估的全部四种适应症，均已获得美国食品药品监督管理局（FDA）授予的快速通道资格。这一重要监管里程碑有望加速相关疗法在神经退行性疾病领域的开发进程。
获得FDA快速通道资格，意味着Polaryx的在研药物将有资格享受更频繁的FDA沟通、滚动审评以及优先审评等利好政策。此举不仅彰显了该疗法解决未满足医疗需求的潜力，也为后续研发提供了明确的加速路径。
Soteria篮子试验设计旨在高效评估单一疗法对多种相关适应症的疗效。此次四款适应症同时获批快速通道资格，进一步验证了Polaryx科研平台的技术优势及其创新疗法的应用前景。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.